These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22291091)

  • 1. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
    Van Driessche A; Berneman ZN; Van Tendeloo VF
    Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
    Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
    Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancer antigen WT1-targeting treatment for the malignancies].
    Oka Y; Kawase I
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 peptide vaccine for the treatment of cancer.
    Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
    Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
    Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
    Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
    Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
    Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors.
    Hirabayashi K; Yanagisawa R; Saito S; Higuchi Y; Koya T; Sano K; Koido S; Okamoto M; Sugiyama H; Nakazawa Y; Shimodaira S
    Anticancer Res; 2018 Apr; 38(4):2227-2234. PubMed ID: 29599343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [WT1-targeting cancer vaccine].
    Sugiyama H
    Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [WT1 peptide cancer vaccine].
    Sugiyama H
    Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
    Koido S; Okamoto M; Shimodaira S; Sugiyama H
    Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
    Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
    Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
    Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
    Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.
    Li Z; Oka Y; Tsuboi A; Masuda T; Tatsumi N; Kawakami M; Fujioka T; Sakaguchi N; Nakajima H; Fujiki F; Udaka K; Oji Y; Kawase I; Sugiyama H
    Int J Hematol; 2005 Dec; 82(5):458-9. PubMed ID: 16533753
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
    Kitagawa K; Oda T; Saito H; Araki A; Gonoi R; Shigemura K; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
    Cancer Immunol Immunother; 2017 Jun; 66(6):787-798. PubMed ID: 28299466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.